Your browser doesn't support javascript.
loading
TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.
Venkatesan, Subramanian; Hoogstraat, Marlous; Caljouw, Ester; Pierson, Tessa; Spoor, Jochem K H; Zeneyedpour, Lona; Dubbink, Hendrikus J; Dekker, Lennard J; van der Kaaij, Mariëlle; Kloezeman, Jenneke; Berghauser Pont, Lotte M E; Besselink, Nicolle J M; Luider, Theo M; Joore, Jos; Martens, John W; Lamfers, Martine L M; Sleijfer, Stefan; Leenstra, Sieger.
Afiliação
  • Venkatesan S; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands.
  • Hoogstraat M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Caljouw E; Center for Personalized Cancer Treatment (CPCT), University Medical Center Utrecht, Utrecht, The Netherlands.
  • Pierson T; Pepscope BV, Utrecht, The Netherlands.
  • Spoor JK; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands.
  • Zeneyedpour L; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands.
  • Dubbink HJ; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Dekker LJ; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • van der Kaaij M; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Kloezeman J; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands.
  • Berghauser Pont LM; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands.
  • Besselink NJ; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands.
  • Luider TM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Joore J; Center for Personalized Cancer Treatment (CPCT), University Medical Center Utrecht, Utrecht, The Netherlands.
  • Martens JW; Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Lamfers ML; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Sleijfer S; Pepscope BV, Utrecht, The Netherlands.
  • Leenstra S; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Oncotarget ; 7(36): 58435-58444, 2016 Sep 06.
Article em En | MEDLINE | ID: mdl-27533080
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Proteína Supressora de Tumor p53 / Glioblastoma / Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas c-bcl-2 / Alvo Mecanístico do Complexo 1 de Rapamicina / Alvo Mecanístico do Complexo 2 de Rapamicina Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Proteína Supressora de Tumor p53 / Glioblastoma / Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas c-bcl-2 / Alvo Mecanístico do Complexo 1 de Rapamicina / Alvo Mecanístico do Complexo 2 de Rapamicina Idioma: En Ano de publicação: 2016 Tipo de documento: Article